Eilean Therapeutics Launches Clinical Trial for Eiletoclax, a Safer BCL2 Inhibitor

Eilean Therapeutics LLC, a biopharmaceutical firm focused on pioneering small molecule inhibitors to address escape mutations in cancers, announced that it has received approval from the Australian Human Research Ethics Committee to commence human trials for eiletoclax, a selective and powerful BCL2 inhibitor, in its Phase 1 clinical program.

The initiation of human dosing for eiletoclax in Australia is a significant milestone for the company, according to Iain Dukes, CEO of Eilean Therapeutics. Dukes noted that eiletoclax has shown promising pre-clinical results, highlighting its advantages over venetoclax-like molecules in terms of safety, tolerability, and feasibility for outpatient treatment. This enables effective targeting of AML and CLL patients, both as a standalone therapy and in combination with other treatments.

Eiletoclax (ZE50-0134) has exhibited superior potency and selectivity against BCL2, a critical pro-survival protein that is excessively present in various cancers. The clinical candidate has shown comparable anti-tumor efficacy to venetoclax in both B cell and myeloid malignancies. Additionally, eiletoclax demonstrated significantly reduced suppression of non-cancerous immune cells, suggesting a better safety profile and greater selectivity.

Eilean Therapeutics LLC, co-founded by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, is dedicated to the discovery and development of top-class small molecule inhibitors targeting escape mutations in blood and solid tumors. The company uses a proprietary hybrid AI platform to meticulously design and expedite the development of these therapies. The mission is to leverage their platform to develop groundbreaking medicines that enhance clinical outcomes for patients with hematologic and solid cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!